Fresnillo PLC (OTCMKTS:FNLPF) Stock Now Rated “Reduce” by Wall Street Brokerages

Shares of Fresnillo PLC (OTCMKTS:FNLPF) have been assigned an average recommendation of “Reduce” from the seven ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the company.

FNLPF has been the topic of a number of analyst reports. Zacks Research upgraded Fresnillo from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Barclays downgraded Fresnillo from an “equal weight” rating to a “strong sell” rating in a research report on Thursday, September 3rd. Jefferies Financial Group initiated coverage on shares of Fresnillo in a research note on Monday, August 3rd. They set a “hold” rating for the company. Finally, Scotiabank raised Fresnillo from a “strong sell” rating to a “hold” rating in a research note on Thursday, July 16th.

Fresnillo Stock Performance

FNLPF stock opened at $33.62 on Friday. The firm has a fifty day moving average price of $36.85 and a two-hundred day moving average price of $42.51. The company has a current ratio of 6.35, a quick ratio of 5.59 and a debt-to-equity ratio of 0.15. Fresnillo has a 1-year low of $28.15 and a 1-year high of $61.00.

About Fresnillo

Fresnillo plc is a Mexico-focused precious metals mining company that explores for, develops and operates mines. Its principal products are silver and gold, with lead and zinc also recovered as by-products at some operations.

The company’s operating portfolio includes mines and processing facilities in several Mexican states, including operations in Zacatecas, Sonora, Chihuahua and Durango. Fresnillo also conducts exploration and development work to identify and advance mineral deposits, and has a joint venture interest in the Juanicipio mine in Zacatecas.

Fresnillo’s roots are in the mining business of Industrias Peñoles, from which it was separated and listed as an independent company in 2008.